HomePharmacologyAntiplatelet

Antiplatelet

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the...

Antiplatelet Treatment with Ticagrelor vs. Clopidogrel in Patients with Chronic Coronary Syndrome

Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention...

Single Antiplatelet Therapy Following Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) has surged as an effective alternative to treat patients with atrial...

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor...

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding...

Cilostazol in Diabetic Patients with Endovascular Peripheral Revascularization: One Step Beyond Symptom Improvement

In patients with peripheral vascular disease (PVD), the presence of diabetes has been significantly associated with increased...

Optimal Duration of DAPT with Oral Anticoagulation After PCI?: 1 Month vs. 3 Months

While the benefits of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor are recognized, its...

AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers...